{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:04:14Z","timestamp":1787166254197,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The feasibility and efficacy of particle beam therapy (PBT) using protons or carbon ions were compared with those of photon-based stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC) via a systematic review and nationwide registry for PBT (Japanese Society for Radiation Oncology [JASTRO] particle therapy committee). Between July 2016 and May 2019, 20 patients with non-metastatic RCC who were treated at six Japanese institutes (using protons at three, using carbon ions at the other three) were registered in the nationwide database and followed up prospectively. The 20 patients comprised 15 men and had a median age of 67 (range: 57\u201388) years. The total radiation dose was 66\u201379.6\u00a0Gy (relative biological effectiveness [RBE]). Over a median follow up of 31\u00a0months, the 3-year rates of overall survival (OS) and local control (LC) were 100% and 94.4%, respectively. No grade\u2009\u2265\u20093 toxicities were observed. Based on a random effects model, a meta-analysis including the present results revealed 3-year OS rates after SBRT and PBT of 75.3% (95% CI: 57.3\u201386.6) and 94.3% (95% CI: 86.8\u201397.6), respectively (P\u2009=\u20090.005), but the difference in LC rates between the two methods was not observed (P\u2009=\u20090.63). PBT is expected to have similar if not better treatment results compared with SBRT for primary renal cancer. In particular, PBT was shown to be effective even for large RCC and could provide a therapeutic option when SBRT is not indicated.<\/jats:p>","DOI":"10.1093\/jrr\/rrad010","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T12:36:37Z","timestamp":1678192597000},"page":"i41-i48","source":"Crossref","is-referenced-by-count":7,"title":["A Japanese registry study and systematic review of particle therapy for renal cell carcinoma"],"prefix":"10.1093","volume":"64","author":[{"given":"Hitoshi","family":"Ishikawa","sequence":"first","affiliation":[{"name":"QST Hospital, National Institutes for Quantum Science and Technology , Inage, Chiba 263-8555 , Japan"},{"name":"Department of Radiation Oncology, University of Tsukuba , Faculty of Medicine, Tsukuba, Ibaraki 305-8575 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Arimura","sequence":"additional","affiliation":[{"name":"Medipolis Proton Therapy and Research Center , Ibusuki, Kagoshima 891-0304 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Tsukuba , Faculty of Medicine, Tsukuba, Ibaraki 305-8575 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemasa","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Gunma University Heavy Ion Medical Center , Maebashi, Gunma 371-8511 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Toyama","sequence":"additional","affiliation":[{"name":"Ion Beam Therapy Center, SAGA-HIMAT Foundation , Tosu, Saga 841-0071 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogino","sequence":"additional","affiliation":[{"name":"Medipolis Proton Therapy and Research Center , Ibusuki, Kagoshima 891-0304 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Okimoto","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Ion Beam Medical Center , Tatsuno, Hyogo 679-5165 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Southern Tohoku Proton Therapy Center , Koriyama, Fukushima 963-8052 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sato","sequence":"additional","affiliation":[{"name":"Proton Therapy Center, Fukui Prefectural Hospital , Fukui, Fukui 910-8526 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Global Center for Biomedical Science and Engineering, Hokkaido University Faculty of Medicine , Hokkaido 060-8638 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Araya","sequence":"additional","affiliation":[{"name":"Proton Therapy Centre, Aizawa Hospital, Matsumoto , Nagano 390-8510 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Ohba","sequence":"additional","affiliation":[{"name":"QST Hospital, National Institutes for Quantum Science and Technology , Inage, Chiba 263-8555 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Umehara","sequence":"additional","affiliation":[{"name":"QST Hospital, National Institutes for Quantum Science and Technology , Inage, Chiba 263-8555 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hokkaido University Faculty of Medicine , Hokkaido 060-8638 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, School of Medicine , Yahaba-Cho, Iwate 028-3694 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Medical and Pharmaceutical University , Takatsuki, Osaka 569-8686 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsuji","sequence":"additional","affiliation":[{"name":"QST Hospital, National Institutes for Quantum Science and Technology , Inage, Chiba 263-8555 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Tsukuba , Faculty of Medicine, Tsukuba, Ibaraki 305-8575 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"2023061915571564100_ref1","volume-title":"Cancer Information Service, National Cancer Center, Tokyo, Japan","author":"Cancer Statistics"},{"key":"2023061915571564100_ref2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1442-2042.2012.03031.x","article-title":"Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update","volume":"19","author":"Fujioka","year":"2012","journal-title":"Int J Urol"},{"key":"2023061915571564100_ref3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"2023061915571564100_ref4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"2023061915571564100_ref5","first-page":"109","article-title":"Partial versus radical nephrectomy in patients with renal cell carcinoma: a systematic review and meta-analysis","volume":"17","author":"Yang","year":"2020","journal-title":"Urol J"},{"key":"2023061915571564100_ref6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urolonc.2022.04.002","article-title":"Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: a systematic review and meta-analysis","volume":"40","author":"Yanagisawa","year":"2022","journal-title":"Urol Oncol"},{"key":"2023061915571564100_ref7","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1007\/s00330-022-08719-1","article-title":"Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma","volume":"32","author":"Chan","year":"2022","journal-title":"Eur Radiol"},{"key":"2023061915571564100_ref8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/iju.14950","article-title":"Carbon-ion radiotherapy for urological cancers","volume":"29","author":"Ishikawa","year":"2022","journal-title":"Int J Urol"},{"key":"2023061915571564100_ref9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","article-title":"Stereotactic body radiation therapy: a novel treatment modality","volume":"7","author":"Lo","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2023061915571564100_ref10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1464-410X.2012.11550.x","article-title":"A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma","volume":"110","author":"Siva","year":"2012","journal-title":"BJU Int"},{"key":"2023061915571564100_ref11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"2023061915571564100_ref12","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.21873\/invivo.12116","article-title":"Proton therapy for primary renal cell carcinoma: the first nationwide retrospective study in Japan","volume":"34","author":"Fukumitsu","year":"2020","journal-title":"In Vivo"},{"key":"2023061915571564100_ref13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/iju.14041","article-title":"Particle therapy for prostate cancer: the past, present and future","volume":"26","author":"Ishikawa","year":"2019","journal-title":"Int J Urol"},{"key":"2023061915571564100_ref14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023061915571564100_ref15","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","author":"US Department of Health and Human Services"},{"key":"2023061915571564100_ref16","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2023061915571564100_ref17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2023061915571564100_ref18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"2023061915571564100_ref19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/0360-3016(91)90249-4","article-title":"On using the linear-quadratic model in daily clinical practice","volume":"20","author":"Yaes","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023061915571564100_ref20","first-page":"201","article-title":"Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiotherapy","volume":"44","author":"Kanai","year":"1999","journal-title":"Radiat Res"},{"key":"2023061915571564100_ref21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiat Oncol"},{"key":"2023061915571564100_ref22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13014-016-0651-5","article-title":"Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma","volume":"11","author":"Yamamoto","year":"2016","journal-title":"Radiat Oncol"},{"key":"2023061915571564100_ref23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"2023061915571564100_ref24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"2023061915571564100_ref25","doi-asserted-by":"crossref","first-page":"153303381882232","DOI":"10.1177\/1533033818822329","article-title":"Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy","volume":"18","author":"Funayama","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"2023061915571564100_ref26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.adro.2019.10.001","article-title":"Nephron-sparing robotic radiosurgical therapy for primary renal cell carcinoma: single-institution experience and review of the literature","volume":"5","author":"Peddada","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"2023061915571564100_ref27","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1111\/cas.13727","article-title":"Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma","volume":"109","author":"Kasuya","year":"2018","journal-title":"Cancer Sci"},{"key":"2023061915571564100_ref28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18632\/oncotarget.26539","article-title":"Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma","volume":"10","author":"Kasuya","year":"2019","journal-title":"Oncotarget"},{"key":"2023061915571564100_ref29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2018.08.010","article-title":"Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature","volume":"131","author":"Francolini","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023061915571564100_ref30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ijrobp.2008.01.043","article-title":"Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience","volume":"72","author":"Nomiya","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023061915571564100_ref31","doi-asserted-by":"crossref","first-page":"i76","DOI":"10.1093\/jrr\/rrw015","article-title":"Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?","volume":"57","author":"Shibamoto","year":"2016","journal-title":"J Radiat Res"},{"key":"2023061915571564100_ref32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"},{"key":"2023061915571564100_ref33","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.ijrobp.2010.05.016","article-title":"Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer","volume":"79","author":"Kadoya","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023061915571564100_ref34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijrobp.2015.10.004","article-title":"The quest for evidence for proton therapy: model-based approach and precision medicine","volume":"95","author":"Widder","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/64\/Supplement_1\/i41\/50625431\/rrad010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/64\/Supplement_1\/i41\/50625431\/rrad010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T11:57:52Z","timestamp":1687175872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/64\/Supplement_1\/i41\/7115897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":34,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2023,4,12]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrad010","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,12]]}}}